Get started
Author

George Cai

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
2025 · Luis Paz-Ares, Hossein Borghaei, et al. · The Lancet · 132
Twelve tips for designing assignments that foster independence in learning
2020 · Christen Rachul, Benjamin Collins, et al. · Medical Teacher · 18
Medical student wellness in Canada: time for a national curriculum framework
2021 · Dax Bourcier, Rena Far, et al. · Canadian Medical Education Journal · 17
PDF
Abstract CT256: EmpowHER-303: A phase 3 study of zanidatamab vs trastuzumab with physician’s choice of chemotherapy in patients with HER2+ metastatic breast cancer whose disease progressed on trastuzumab deruxtecan
2025 · Sara M. Tolaney, Javier Cortes, et al. · Cancer Research · 3
Review of icatibant use in the Winnipeg Regional Health Authority
2020 · George Cai, Colin Barber, et al. · Allergy Asthma and Clinical Immunology · 2
PDF
Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).
2026 · Luis G. Paz-Ares, Hossein Borghaei, et al. · Journal of Clinical Oncology · 1
PP01.144: Patient-Reported Outcomes (PROs) from IMforte: A Phase 3 Study of First-Line Maintenance Treatment with Lurbinectedin + Atezolizumab Versus Atezolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
2026 · Roy S. Herbst, Luis Paz-Ares, et al. · Journal of Thoracic Oncology · 1
Spontaneous, simultaneous bilateral osteonecrosis of the femoral heads in a patient with sideroblastic anaemia with B-cell immunodeficiency, periodic fever and developmental delay syndrome
2023 · George Cai, Dev Jayaraman · BMJ Case Reports · 1
PDF
Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study.
2026 · Julia Lynne Glade Bender, Joseph Gerald Pressey, et al. · Journal of Clinical Oncology
Summarizing the 2024 immunotherapy manual of the Canadian society of allergy and clinical immunology
2026 · Aria Bruton Joe, George Cai, et al. · Allergy Asthma and Clinical Immunology
Atypical X-linked lymphoproliferative syndrome type 2 presenting with polysaccharide antibody deficiency and infantile Langerhans cell histiocytosis
2026 · Jason Z.X. Chen, George Cai, et al. · LymphoSign Journal
Abstract P5-03-15: EmpowHER 303: A phase 3 study to evaluate the efficacy and safety of zanidatamab vs trastuzumab with chemotherapy in patients (pts) with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan
2025 · Sara M Tolaney, Javier Cortes, et al. · Clinical Cancer Research
Never Say Never—Delayed and Unusual Presentations of XLA in Two Patients with a Kinase-Domain Variant
2025 · George Cai, Andrew Wong-Pack, et al. · Journal of Human Immunity
Insights into EBV Infection in an Adult with X-Linked Lymphoproliferative Syndrome
2025 · Andrew Wong-Pack, Vivian Szeto, et al. · Journal of Human Immunity
Review of Icatibant Use in the Winnipeg Regional Health Authority
2020 · George Cai, Chrystyna Kalicinsky, et al. · Journal of Allergy and Clinical Immunology
PDF
Anaphylaxis exclusivity in a single Citrus species
2015 · George Cai, Jason Kihyuk Lee · Annals of Allergy Asthma & Immunology
Works count: 16
Citation count: 175
H-index: 3
I10-index: 3
Year
Topic
Type